1. Home
  2. ABUS vs ITRG Comparison

ABUS vs ITRG Comparison

Compare ABUS & ITRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.61

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$3.18

Market Cap

586.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
ITRG
Founded
2005
1997
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
929.6M
586.3M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
ABUS
ITRG
Price
$4.61
$3.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.00
$5.13
AVG Volume (30 Days)
1.9M
2.8M
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
55.26
N/A
EPS
N/A
N/A
Revenue
$14,083,000.00
N/A
Revenue This Year
N/A
$67.34
Revenue Next Year
$783.24
$25.89
P/E Ratio
N/A
$45.07
Revenue Growth
128.21
N/A
52 Week Low
$3.04
$1.43
52 Week High
$5.10
$4.87

Technical Indicators

Market Signals
Indicator
ABUS
ITRG
Relative Strength Index (RSI) 55.64 54.84
Support Level $4.19 $2.60
Resistance Level $4.64 $3.31
Average True Range (ATR) 0.19 0.17
MACD 0.03 0.07
Stochastic Oscillator 76.61 89.23

Price Performance

Historical Comparison
ABUS
ITRG

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

Share on Social Networks: